SK17922002A3 - Obdoby gabapentínu na liečenie porúch spánku - Google Patents
Obdoby gabapentínu na liečenie porúch spánku Download PDFInfo
- Publication number
- SK17922002A3 SK17922002A3 SK1792-2002A SK17922002A SK17922002A3 SK 17922002 A3 SK17922002 A3 SK 17922002A3 SK 17922002 A SK17922002 A SK 17922002A SK 17922002 A3 SK17922002 A3 SK 17922002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- aminomethyl
- acetic acid
- cyclopentyl
- tert
- butyl
- Prior art date
Links
- 208000019116 sleep disease Diseases 0.000 title claims description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical class OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 13
- 206010022437 insomnia Diseases 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 134
- -1 amino, aminomethyl Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- KKXFMWXZXDUYBF-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCC[C@@H](C)C[C@H](CN)CC(O)=O KKXFMWXZXDUYBF-BDAKNGLRSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 claims description 2
- DNHPJOLWCOXHOV-JTQLQIEISA-N 2-[(1r)-1-(aminomethyl)-2,2-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC[C@@]1(CN)CC(O)=O DNHPJOLWCOXHOV-JTQLQIEISA-N 0.000 claims description 2
- SIKUEILNNOXUAZ-LBPRGKRZSA-N 2-[(1r)-1-(aminomethyl)-3,3-diethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC[C@](CN)(CC(O)=O)C1 SIKUEILNNOXUAZ-LBPRGKRZSA-N 0.000 claims description 2
- OPAXRDNEIABTQI-SECBINFHSA-N 2-[(1s)-1-(aminomethyl)-2,2-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC[C@]1(CN)CC(O)=O OPAXRDNEIABTQI-SECBINFHSA-N 0.000 claims description 2
- DNHPJOLWCOXHOV-SNVBAGLBSA-N 2-[(1s)-1-(aminomethyl)-2,2-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC[C@]1(CN)CC(O)=O DNHPJOLWCOXHOV-SNVBAGLBSA-N 0.000 claims description 2
- SIKUEILNNOXUAZ-GFCCVEGCSA-N 2-[(1s)-1-(aminomethyl)-3,3-diethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC[C@@](CN)(CC(O)=O)C1 SIKUEILNNOXUAZ-GFCCVEGCSA-N 0.000 claims description 2
- QZBKCCCUSMQVTC-SNVBAGLBSA-N 2-[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CC[C@@](CN)(CC(O)=O)C1 QZBKCCCUSMQVTC-SNVBAGLBSA-N 0.000 claims description 2
- VVJFYFLGWOCDQD-HTQZYQBOSA-N 2-[(2r,5r)-1-(aminomethyl)-2,5-dimethylcyclopentyl]acetic acid Chemical compound C[C@@H]1CC[C@@H](C)C1(CN)CC(O)=O VVJFYFLGWOCDQD-HTQZYQBOSA-N 0.000 claims description 2
- KOPGUPUTANQKJY-NXEZZACHSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-diethylcyclopentyl]acetic acid Chemical compound CC[C@@H]1CC(CN)(CC(O)=O)C[C@H]1CC KOPGUPUTANQKJY-NXEZZACHSA-N 0.000 claims description 2
- XRAYXEBZNYLCBY-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,4,4-tetramethylcyclobutyl]acetic acid Chemical compound CC1(C)CC(C)(C)C1(CN)CC(O)=O XRAYXEBZNYLCBY-UHFFFAOYSA-N 0.000 claims description 2
- SEPPWOWOFXDAAP-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3,4,4-tetraethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC(CN)(CC(O)=O)CC1(CC)CC SEPPWOWOFXDAAP-UHFFFAOYSA-N 0.000 claims description 2
- FLNCTXNXKXKYGH-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3,4,4-tetramethylcyclopentyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)CC1(C)C FLNCTXNXKXKYGH-UHFFFAOYSA-N 0.000 claims description 2
- BSRBEUFYGVVBLO-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-diethylcyclobutyl]acetic acid Chemical compound CCC1(CC)CC(CN)(CC(O)=O)C1 BSRBEUFYGVVBLO-UHFFFAOYSA-N 0.000 claims description 2
- FUDBUFIPBPLPHY-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-diphenylcyclobutyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC1(C=1C=CC=CC=1)C1=CC=CC=C1 FUDBUFIPBPLPHY-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 3
- QZBKCCCUSMQVTC-JTQLQIEISA-N 2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CC[C@](CN)(CC(O)=O)C1 QZBKCCCUSMQVTC-JTQLQIEISA-N 0.000 claims 1
- HBFZWKRCDVWGSA-WOJBJXKFSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-dibenzylcyclopentyl]acetic acid Chemical compound C([C@@H]1CC(C[C@H]1CC=1C=CC=CC=1)(CC(O)=O)CN)C1=CC=CC=C1 HBFZWKRCDVWGSA-WOJBJXKFSA-N 0.000 claims 1
- IUVMAUQEZFTTFB-HTQZYQBOSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound C[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C IUVMAUQEZFTTFB-HTQZYQBOSA-N 0.000 claims 1
- BHQDRZBQUNHTBG-ROUUACIJSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-diphenylcyclopentyl]acetic acid Chemical compound C1([C@H]2[C@@H](CC(C2)(CC(O)=O)CN)C=2C=CC=CC=2)=CC=CC=C1 BHQDRZBQUNHTBG-ROUUACIJSA-N 0.000 claims 1
- DPSPUVHOQGLSSE-VXGBXAGGSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-ditert-butylcyclopentyl]acetic acid Chemical compound CC(C)(C)[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C(C)(C)C DPSPUVHOQGLSSE-VXGBXAGGSA-N 0.000 claims 1
- KOPGUPUTANQKJY-UWVGGRQHSA-N 2-[(3s,4s)-1-(aminomethyl)-3,4-diethylcyclopentyl]acetic acid Chemical compound CC[C@H]1CC(CN)(CC(O)=O)C[C@@H]1CC KOPGUPUTANQKJY-UWVGGRQHSA-N 0.000 claims 1
- PSOWEDFUUXXEHX-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,5,5-tetramethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC(C)(C)C1(CN)CC(O)=O PSOWEDFUUXXEHX-UHFFFAOYSA-N 0.000 claims 1
- UWYKQWDIAKQCEJ-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-di(propan-2-yl)cyclobutyl]acetic acid Chemical compound CC(C)C1(C(C)C)CC(CN)(CC(O)=O)C1 UWYKQWDIAKQCEJ-UHFFFAOYSA-N 0.000 claims 1
- QZBKCCCUSMQVTC-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC(CN)(CC(O)=O)C1 QZBKCCCUSMQVTC-UHFFFAOYSA-N 0.000 claims 1
- UYWXMKBUXWKTHD-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-tert-butyl-4-ethylcyclopentyl]acetic acid Chemical compound CCC1CC(CN)(CC(O)=O)CC1C(C)(C)C UYWXMKBUXWKTHD-UHFFFAOYSA-N 0.000 claims 1
- UKPVCXAEJOKSRI-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclobutyl]acetic acid;hydrochloride Chemical compound Cl.OC(=O)CC1(CN)CCC1 UKPVCXAEJOKSRI-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000008452 non REM sleep Effects 0.000 description 8
- 230000007958 sleep Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000573 anti-seizure effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- OPAXRDNEIABTQI-VIFPVBQESA-N 2-[(1r)-1-(aminomethyl)-2,2-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC[C@@]1(CN)CC(O)=O OPAXRDNEIABTQI-VIFPVBQESA-N 0.000 description 1
- VVJFYFLGWOCDQD-YUMQZZPRSA-N 2-[(2s,5s)-1-(aminomethyl)-2,5-dimethylcyclopentyl]acetic acid Chemical compound C[C@H]1CC[C@H](C)C1(CN)CC(O)=O VVJFYFLGWOCDQD-YUMQZZPRSA-N 0.000 description 1
- ZKPYVRKWQDIKJF-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,3,3,4,4-hexamethylcyclobutyl]acetic acid Chemical compound CC1(C)C(C)(C)C(CN)(CC(O)=O)C1(C)C ZKPYVRKWQDIKJF-UHFFFAOYSA-N 0.000 description 1
- WPAARGGOPBXIAH-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,4-dimethylcyclobutyl]acetic acid Chemical compound CC1CC(C)C1(CN)CC(O)=O WPAARGGOPBXIAH-UHFFFAOYSA-N 0.000 description 1
- SRLZVTNHASZZSM-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dibenzylcyclobutyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 SRLZVTNHASZZSM-UHFFFAOYSA-N 0.000 description 1
- XEXRZUKGFDRWLE-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)C1 XEXRZUKGFDRWLE-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 229940121985 Non-benzodiazepine hypnotic Drugs 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960005008 doxylamine succinate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21417100P | 2000-06-26 | 2000-06-26 | |
| PCT/US2001/016343 WO2002000209A2 (en) | 2000-06-26 | 2001-05-18 | Gabapentin analogues for sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK17922002A3 true SK17922002A3 (sk) | 2003-11-04 |
Family
ID=22798045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1792-2002A SK17922002A3 (sk) | 2000-06-26 | 2001-05-18 | Obdoby gabapentínu na liečenie porúch spánku |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7141606B2 (he) |
| EP (1) | EP1296671B1 (he) |
| JP (1) | JP3909842B2 (he) |
| KR (1) | KR100785182B1 (he) |
| CN (1) | CN1279900C (he) |
| AT (1) | ATE390133T1 (he) |
| AU (2) | AU6473601A (he) |
| BR (1) | BR0111913A (he) |
| CA (1) | CA2414008C (he) |
| CZ (1) | CZ20024110A3 (he) |
| DE (1) | DE60133389T2 (he) |
| DK (1) | DK1296671T3 (he) |
| ES (1) | ES2300332T3 (he) |
| HK (1) | HK1056681A1 (he) |
| HU (1) | HUP0300833A3 (he) |
| IL (2) | IL152770A0 (he) |
| MX (1) | MXPA02010668A (he) |
| NZ (1) | NZ522480A (he) |
| PL (1) | PL359872A1 (he) |
| PT (1) | PT1296671E (he) |
| SK (1) | SK17922002A3 (he) |
| TW (1) | TWI298020B (he) |
| WO (1) | WO2002000209A2 (he) |
| ZA (1) | ZA200209418B (he) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12504A (en) | 2001-04-19 | 2006-05-29 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids. |
| WO2002100392A1 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7420002B2 (en) | 2001-06-11 | 2008-09-02 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS |
| WO2003080588A1 (en) | 2002-03-20 | 2003-10-02 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
| US7183259B2 (en) | 2002-05-17 | 2007-02-27 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| US7060727B2 (en) | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| WO2004054564A1 (en) * | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Gabapentin analogues for fibromyalgia and other related disorders |
| WO2004093827A2 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| MXPA06002731A (es) | 2003-09-11 | 2006-06-05 | Xenoport Inc | Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba. |
| JP5107576B2 (ja) | 2003-09-17 | 2012-12-26 | ゼノポート，インコーポレイティド | Ｇａｂａ類似体のプロドラッグを使用する不穏下肢症候群の治療または予防 |
| MXPA06004088A (es) | 2003-10-14 | 2006-06-27 | Xenoport Inc | Forma cristalina de un analogo del acido gamma-aminobutirico. |
| JP4613031B2 (ja) * | 2004-05-06 | 2011-01-12 | エスエス製薬株式会社 | 催眠剤組成物 |
| JP2005325070A (ja) * | 2004-05-14 | 2005-11-24 | Ss Pharmaceut Co Ltd | 睡眠改善剤 |
| US8795725B2 (en) | 2004-11-04 | 2014-08-05 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
| EP1893244A4 (en) | 2005-06-23 | 2009-06-24 | Univ Emory | AGENTS FOR IMAGING |
| KR20070070307A (ko) * | 2005-08-24 | 2007-07-04 | 에스에스 세야쿠 가부시키 가이샤 | 수면 개선 의약 조성물 |
| CA2640402C (en) * | 2006-03-06 | 2012-01-03 | Pfizer Products Inc. | Alpha-2-delta ligands for non-restorative sleep |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| CA2706575C (en) | 2008-01-25 | 2015-07-14 | Xenoport, Inc. | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
| WO2009094563A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use |
| ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| WO2014117176A1 (en) | 2013-01-28 | 2014-07-31 | Lopez Hector L | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
| TWI733817B (zh) * | 2016-05-26 | 2021-07-21 | 日商阿明諾股份有限公司 | 睡眠改善劑 |
| CN114621119A (zh) | 2018-05-14 | 2022-06-14 | 昌郁医药公司 | 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5084479A (en) * | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| DE19525598C2 (de) * | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| KR100487032B1 (ko) * | 1996-03-14 | 2005-12-21 | 워너-램버트 캄파니 엘엘씨 | 약제로서신규한브리지된시클릭아미노산 |
| US6372792B1 (en) * | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| PL199794B1 (pl) | 1997-10-27 | 2008-10-31 | Warner Lambert Co | Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów |
| JP2002520277A (ja) * | 1998-07-09 | 2002-07-09 | ワーナー−ランバート・カンパニー | 不眠症を治療する方法 |
| CA2371395A1 (en) * | 1999-06-02 | 2000-12-07 | Warner Lambert Company | Amino heterocycles useful as pharmaceutical agents |
| HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| KR20020060988A (ko) * | 1999-12-08 | 2002-07-19 | 워너-램버트 캄파니 | 시클릭 아미노산의 입체선택적 합성 방법 |
| GB9930083D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
-
2001
- 2001-05-18 DE DE60133389T patent/DE60133389T2/de not_active Expired - Lifetime
- 2001-05-18 WO PCT/US2001/016343 patent/WO2002000209A2/en active IP Right Grant
- 2001-05-18 BR BR0111913-3A patent/BR0111913A/pt not_active Application Discontinuation
- 2001-05-18 NZ NZ522480A patent/NZ522480A/en unknown
- 2001-05-18 AT AT01939192T patent/ATE390133T1/de not_active IP Right Cessation
- 2001-05-18 JP JP2002504991A patent/JP3909842B2/ja not_active Expired - Fee Related
- 2001-05-18 EP EP01939192A patent/EP1296671B1/en not_active Expired - Lifetime
- 2001-05-18 CN CNB018110487A patent/CN1279900C/zh not_active Expired - Fee Related
- 2001-05-18 HU HU0300833A patent/HUP0300833A3/hu unknown
- 2001-05-18 KR KR1020027017609A patent/KR100785182B1/ko not_active Expired - Fee Related
- 2001-05-18 AU AU6473601A patent/AU6473601A/xx active Pending
- 2001-05-18 SK SK1792-2002A patent/SK17922002A3/sk not_active Application Discontinuation
- 2001-05-18 IL IL15277001A patent/IL152770A0/xx unknown
- 2001-05-18 ES ES01939192T patent/ES2300332T3/es not_active Expired - Lifetime
- 2001-05-18 PT PT01939192T patent/PT1296671E/pt unknown
- 2001-05-18 DK DK01939192T patent/DK1296671T3/da active
- 2001-05-18 MX MXPA02010668A patent/MXPA02010668A/es active IP Right Grant
- 2001-05-18 US US10/297,827 patent/US7141606B2/en not_active Expired - Fee Related
- 2001-05-18 PL PL35987201A patent/PL359872A1/xx not_active Application Discontinuation
- 2001-05-18 AU AU2001264736A patent/AU2001264736B2/en not_active Ceased
- 2001-05-18 CZ CZ20024110A patent/CZ20024110A3/cs unknown
- 2001-05-18 CA CA2414008A patent/CA2414008C/en not_active Expired - Fee Related
- 2001-06-19 TW TW090114841A patent/TWI298020B/zh not_active IP Right Cessation
-
2002
- 2002-11-11 IL IL152770A patent/IL152770A/he not_active IP Right Cessation
- 2002-11-19 ZA ZA200209418A patent/ZA200209418B/en unknown
-
2003
- 2003-12-11 HK HK03109027A patent/HK1056681A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK17922002A3 (sk) | Obdoby gabapentínu na liečenie porúch spánku | |
| AU2001264736A1 (en) | Gabapentin analogues for sleep disorders | |
| ES2244103T3 (es) | Remedio para enfermedades neurodegenerativas. | |
| US4877620A (en) | Ibuprofen-containing medicament | |
| US5200558A (en) | S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset-hastened enhanced analgesics | |
| PT867179E (pt) | Composicao de esteres de l-dopa | |
| IE58314B1 (en) | Pharmaceutical products providing enhanced analgasia | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| CZ20033066A3 (cs) | Kapalná farmaceutická směs | |
| SK284923B6 (sk) | Zmes liečiv s antidepresívnym účinkom obsahujúca 2-amino-4,5,6,7- tetrahydro-6-propylaminobenzotiazol a sertralín a jej použitie | |
| JP2002520277A (ja) | 不眠症を治療する方法 | |
| IE903717A1 (en) | S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset hastened enhanced analgesics | |
| US3557292A (en) | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine | |
| US5519057A (en) | Ibuprofen-containing medicament | |
| US4089957A (en) | Therapeutic compositions against recurrent thrombosis | |
| US4389415A (en) | Method of treating hypertension | |
| DE2841170A1 (de) | Hypnotikum | |
| US3932652A (en) | Antidepressant compositions | |
| CA2640402C (en) | Alpha-2-delta ligands for non-restorative sleep | |
| ES2326355B1 (es) | Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico. | |
| US4537907A (en) | Hypnotic composition and method of inducing sleep | |
| EP0003353A1 (en) | A pharmaceutical composition for oral administration for treating hypertension | |
| JP2002520278A (ja) | Ｇａｂａ類縁体での腎仙痛の治療 | |
| MXPA00009677A (en) | Oral liquid antidepressant solution | |
| RU2000124937A (ru) | Новые препараты в виде солей n-метил-n-((1r)-1-(n-метил-n-((1r)-1-(метилкарбамоил)-2-фенилэтил)карбамои л)-2-(2-нафтил)этил)амида(2е)-5-амино-5-метилгексен-2-овой кислоты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |